Form 4: CRISPR Therapeutics Executive James R. Kasinger Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, reports the acquisition and disposal of common shares and restricted stock units related to vesting and tax obligations.

Summary

  • James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, filed a Form 4 detailing changes in beneficial ownership.
  • On March 10, 2025, Kasinger acquired 5,500 common shares through the vesting of restricted stock units.
  • On March 11, 2025, he sold 2,850 shares at $42.42 to cover tax withholding obligations related to vesting.
  • Also on March 11, 2025, he acquired 2,250 common shares through the vesting of restricted stock units.
  • On March 12, 2025, he sold 1,116 shares at $43.32 to cover tax withholding obligations.
  • Following these transactions, Kasinger directly owns 78,664 common shares and 11,000 restricted stock units.

Sentiment

Score: 5

Explanation: The document reflects routine executive stock transactions related to compensation and tax obligations, indicating a neutral sentiment.

Industry Context

Executive stock transactions are a normal part of corporate governance and compensation practices. The sale of shares to cover tax obligations is a common occurrence when restricted stock units vest.

Stakeholder Impact

  • The transactions may have a minor impact on shareholders due to the executive's stock sales, but the overall impact is likely minimal.

Key Dates

DateDescription
03/10/2023Restricted stock unit award granted with respect to 22,000 Common Shares, vesting quarterly from March 10, 2024.
03/11/2021Restricted stock unit award granted with respect to 9,000 Common Shares, vesting quarterly from March 11, 2022.
03/10/2025Acquisition of 5,500 common shares through RSU vesting.
03/11/2025Sale of 2,850 common shares at $42.42 and acquisition of 2,250 common shares through RSU vesting.
03/12/2025Sale of 1,116 common shares at $43.32.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.